Oculis Holding AG announced its participation in the 47th Annual Goldman Sachs Global Healthcare Conference, where it will present updates on its late-stage biopharmaceutical portfolio targeting neuro-ophthalmic and ophthalmic diseases. Key highlights include Privosegtor, a neuroprotective drug with FDA Breakthrough Therapy and EMA PRIME designations for optic neuritis, and Licaminlimab, a topical treatment for dry eye disease using a genotype-based approach. The company aims to deliver pivotal clinical trial results soon, focusing on innovative treatments to improve eye care and address significant unmet medical needs. The presentation will be held on June 9, 2026, with opportunities for investor meetings.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
